company background image
GLPG logo

Galapagos NasdaqGS:GLPG Stock Report

Last Price

US$32.95

Market Cap

US$2.2b

7D

-3.0%

1Y

-12.4%

Updated

27 Mar, 2024

Data

Company Financials +

GLPG Stock Overview

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of?various medicines for high unmet medical need.

GLPG fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Galapagos NV Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Galapagos
Historical stock prices
Current Share Price€32.95
52 Week High€45.21
52 Week Low€31.86
Beta0.027
1 Month Change-9.73%
3 Month Change-19.06%
1 Year Change-12.44%
3 Year Change-57.26%
5 Year Change-73.10%
Change since IPO319.75%

Recent News & Updates

Galapagos: Pipeline Still Progressing Despite Financial Volatility

Mar 07

Recent updates

Galapagos: Pipeline Still Progressing Despite Financial Volatility

Mar 07

Galapagos: Trading At Discount To Cash With A Fast-Growing Marketed Product

Oct 10

EMA panel approves amending label for Galapagos' Jyseleca on testicular function effects

Oct 03

Galapagos stock dips after Jefferies slashes rating citing challenges ahead

Jul 25

Galapagos: Can The Company Turn Around?

May 19

Galapagos: A History Of Disruptive Failures

Feb 22

Galapagos: The Investment Thesis Is More Appealing Than Ever

Dec 02

Galapagos, Gilead's Selection study on filgotinib in ulcerative colitis published in the Lancet

Jun 04

Galapagos reports Q1 results

May 06

Galapagos: Market Values Pipeline Below $0

Dec 30

Galapagos candidate shows positive action in IPF proof-of-concept study

Nov 30

Galapagos NV 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Galapagos Is A Buy Despite Setback In The U.S.

Oct 23

Shareholder Returns

GLPGUS BiotechsUS Market
7D-3.0%0.9%0.4%
1Y-12.4%10.3%28.8%

Return vs Industry: GLPG underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: GLPG underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is GLPG's price volatile compared to industry and market?
GLPG volatility
GLPG Average Weekly Movement3.7%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: GLPG's share price has been volatile over the past 3 months.

Volatility Over Time: GLPG's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19991,233Paul Stoffelshttps://www.glpg.com

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis.

Galapagos NV Fundamentals Summary

How do Galapagos's earnings and revenue compare to its market cap?
GLPG fundamental statistics
Market capUS$2.16b
Earnings (TTM)-US$4.32m
Revenue (TTM)US$259.53m

8.3x

P/S Ratio

-501.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GLPG income statement (TTM)
Revenue€239.72m
Cost of Revenue€241.29m
Gross Profit-€1.57m
Other Expenses€2.42m
Earnings-€3.99m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Mar 28, 2024

Earnings per share (EPS)-0.061
Gross Margin-0.65%
Net Profit Margin-1.66%
Debt/Equity Ratio0%

How did GLPG perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.